Perspectives/NNS
of/IN
International/JJ
Human/JJ
Epigenome/JJ
Consortium/NN
./.
====================
As/IN
the/DT
International/JJ
Human/JJ
Epigenome/JJ
Consortium/NN
(/(
IHEC/NN
)/)
launched/VBD
officially/RB
at/IN
the/DT
2010/CD
Washington/NN
meeting/VBG
,/,
a/DT
giant/JJ
step/NN
toward/IN
the/DT
conquest/JJS
of/IN
unexplored/JJ
regions/NNS
of/IN
the/DT
human/JJ
genome/NN
has/VBZ
begun/VBN
./.
====================
IHEC/NN
aims/VBZ
at/IN
the/DT
production/NN
of/IN
1,000/CD
reference/VBP
epigenomes/NNS
to/TO
the/DT
international/JJ
scientific/JJ
community/NN
for/IN
next/JJ
7-10/CD
years/NNS
./.
====================
Seven/CD
member/NN
institutions/NNS
,/,
including/VBG
South/NN
Korea/NN
,/,
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
KNIH/NN
)/)
,/,
will/MD
produce/VB
25-200/CD
reference/VBP
epigenomes/NNS
individually/RB
,/,
and/CC
the/DT
produced/VBN
data/NNS
will/MD
be/VB
publically/RB
available/JJ
by/IN
using/VBG
a/DT
data/NNS
center/NN
./.
====================
Epigenome/DT
data/NNS
will/MD
cover/RB
from/IN
whole/JJ
genome/NN
bisulfite/NN
sequencing/NN
,/,
histone/NN
modification/NN
,/,
and/CC
chromatin/NN
access/NN
information/NN
to/TO
miRNA-seq/VB
./.
====================
The/DT
final/JJ
goal/NN
of/IN
IHEC/NN
is/VBZ
the/DT
production/NN
of/IN
reference/NN
maps/VBZ
of/IN
human/JJ
epigenomes/NNS
for/IN
key/JJ
cellular/JJ
status/NN
relevant/JJ
to/TO
health/NN
and/CC
disease/NN
./.
====================
Epigenome/JJ
is/VBZ
the/DT
word/NN
describing/VBG
the/DT
thing/JJ
that/DT
is/VBZ
not/RB
included/VBN
in/IN
genetics/NNS
./.
====================
``/CD
Epi/NN
''/CD
means/NNS
upon/IN
or/CC
outside/IN
;/:
so/RB
,/,
a/DT
direct/JJ
translation/NN
is/VBZ
``/CD
the/DT
thing/JJ
that/DT
is/VBZ
not/RB
related/JJ
with/IN
genetics/NNS
or/CC
above/JJ
genetics/NNS
./.
''/CD
====================
Practically/RB
,/,
it/PRP
means/NNS
gene/NN
regulation/NN
phenomena/NNS
,/,
including/VBG
by/IN
means/NNS
of/IN
DNA/NN
methylation/NN
,/,
histone/NN
modification/NN
,/,
and/CC
miRNA/JJ
./.
====================
To/TO
explore/VB
epigenomic/JJ
regulation/NN
,/,
International/NNP
Human/JJ
Epigenome/JJ
Consortium/NN
(/(
IHEC/NN
)/)
was/VBD
initiated/VBN
to/TO
profile/VB
the/DT
epigenome/JJ
of/IN
all/DT
human/JJ
cell/NN
types/NNS
./.
====================
To/TO
understand/VB
the/DT
current/JJ
IHEC/NN
,/,
it/PRP
is/VBZ
required/VBN
to/TO
turn/NN
back/RB
into/IN
the/DT
initial/JJ
steps/NNS
for/IN
fostering/VBG
this/DT
consortium/NN
./.
====================
It/PRP
has/VBZ
passed/VBN
more/RBR
than/IN
a/DT
decade/JJ
after/IN
completion/NN
of/IN
the/DT
human/JJ
genome/NN
project/JJ
,/,
and/CC
several/JJ
efforts/NNS
were/VBD
conceived/VBN
to/TO
accelerate/VB
finding/VBG
disease-causing/VBG
genetic/JJ
variations/NNS
,/,
such/JJ
as/IN
genome-wide/RB
association/NN
study/RB
(/(
2003/CD
)/)
,/,
Encyclopedia/NN
of/IN
DNA/NN
Element/NN
(/(
ENCODE/NNP
,/,
2003/CD
)/)
,/,
The/DT
Cancer/NN
Genome/NNP
Atlas/IN
(/(
TCGA/NNP
,/,
2006/CD
)/)
,/,
International/NNP
Cancer/NN
Genome/NNP
Consortium/NN
(/(
ICGC/NN
,/,
2008/CD
)/)
,/,
and/CC
National/JJ
Institutes/NNS
of/IN
Health/DT
(/(
NIH/NN
)/)
Roadmap/NNP
Epigenomics/NNS
(/(
2008/CD
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
IHEC/NN
was/VBD
born/VBN
with/IN
ground/JJ
making/VBG
effort/NN
of/IN
these/DT
several/JJ
international/JJ
consortiums/VBZ
./.
====================
Although/IN
the/DT
Human/JJ
Genome/NN
Project/JJ
,/,
which/WDT
defined/VBN
the/DT
exact/JJ
sequence/NN
of/IN
3/CD
billion/NN
bases/NNS
in/IN
DNA/NN
,/,
is/VBZ
one/CD
of/IN
the/DT
big/NN
milestones/NNS
in/IN
genome/NN
research/NN
,/,
cataloging/VBG
DNA/NN
sequence/NN
information/NN
has/VBZ
a/DT
limited/JJ
effect/NN
on/IN
defining/VBG
whole/JJ
varieties/VBZ
of/IN
genome/NN
variations/NNS
that/IN
are/VBP
expected/VBN
to/TO
be/VB
crucial/JJ
cause/VBP
of/IN
disease/NN
./.
====================
Also/RB
,/,
the/DT
sequence/NN
itself/PRP
does/VBZ
not/RB
provide/VB
how/WRB
the/DT
genome/NN
is/VBZ
packaged/VBN
in/IN
chromosomes/NNS
and/CC
chromatin/NN
,/,
which/WDT
is/VBZ
essential/JJ
for/IN
organismal/JJ
development/NN
and/CC
differentiation/NN
./.
====================
So/RB
,/,
epigenetic/JJ
regulation/NN
,/,
in/IN
addition/NN
to/TO
transcription/NN
factor/NN
binding/NN
profile/NN
,/,
is/VBZ
emerging/VBG
as/IN
a/DT
powerful/JJ
tool/NN
to/TO
identify/VB
disease/NN
correlation/NN
with/IN
genome/NN
information/NN
[/(
1/CD
]/)
./.
====================
In/IN
2004/CD
,/,
a/DT
National/JJ
Cancer/NN
Institute/JJ
(/(
NCI/NN
)/)
-sponsored/JJ
workshop/NN
,/,
Epigenetic/JJ
Mechanisms/NNS
in/IN
Cancer/NN
,/,
had/VBD
initiating/VBG
discussions/NNS
of/IN
necessity/NN
of/IN
the/DT
Human/JJ
Epigenome/JJ
Project/JJ
,/,
which/WDT
will/MD
be/VB
in/IN
parallel/JJ
with/IN
the/DT
Human/JJ
Genome/NN
Project/JJ
./.
====================
In/IN
2005/CD
,/,
there/EX
was/VBD
a/DT
special/JJ
workshop/NN
on/IN
the/DT
BLUEPRINT/NN
for/IN
a/DT
Human/JJ
Epigenome/JJ
Project/JJ
,/,
the/DT
American/NN
Association/NN
of/IN
Cancer/NN
Research/NN
(/(
AACR/NN
)/)
Human/JJ
Epigenome/JJ
Workshop/NNP
,/,
on/IN
defining/VBG
human/JJ
epigenomes/NNS
at/IN
high/JJ
resolution/NN
./.
====================
The/DT
consensus/NN
of/IN
workshop/NN
participants/NNS
was/VBD
that/DT
there/EX
were/VBD
compelling/VBG
reasons/NNS
from/IN
both/DT
scientific/JJ
and/CC
public/JJ
health/NN
perspectives/NNS
to/TO
initiate/VB
a/DT
human/JJ
epigenome/JJ
project/VB
that/DT
could/MD
take/VB
full/JJ
advantage/NN
of/IN
advances/NNS
in/IN
several/JJ
existing/VBG
US/NN
and/CC
European/JJ
initiatives/VBZ
./.
====================
In/IN
2006/CD
,/,
TCGA/NN
began/VBD
as/IN
a/DT
3-year/JJ
pilot/NN
with/IN
an/DT
investment/JJ
of/IN
$/NN
50/CD
million/NN
each/DT
from/IN
the/DT
NCI/NN
and/CC
National/JJ
Human/JJ
Genome/NN
Research/NN
Institute/JJ
(/(
NHGRI/NN
)/)
to/TO
analyze/VB
the/DT
genome/NN
and/CC
epigenome/JJ
of/IN
20/CD
types/NNS
of/IN
cancer/NN
tissue/NN
./.
====================
In/IN
2008/CD
,/,
amending/VBG
the/DT
TCGA/NN
,/,
international/JJ
efforts/NNS
were/VBD
assembled/VBN
to/TO
analyze/VB
cancer/NN
genome/epigenome/NN
variation/NN
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
ICGC/NN
was/VBD
launched/VBN
in/IN
2008/CD
to/TO
coordinate/VB
large-scale/JJ
cancer/NN
(/(
epi/NN
)/)
genome/NN
studies/NNS
in/IN
tumors/NNS
from/IN
50/CD
cancer/NN
types/NNS
and/or/CC
subtypes/NNS
,/,
with/IN
participation/NN
of/IN
15/CD
countries/NNS
./.
====================
ICGC/NN
is/VBZ
focused/VBN
on/IN
obtaining/VBG
a/DT
comprehensive/JJ
description/NN
of/IN
genomic/JJ
,/,
transcriptomic/JJ
,/,
and/CC
epigenomic/JJ
changes/NNS
in/IN
50/CD
different/JJ
tumor/NN
types/NNS
./.
====================
Also/RB
,/,
the/DT
international/JJ
Alliance/NN
for/IN
Human/JJ
Epigenetics/NNS
and/CC
Disease/NN
(/(
AHEAD/NN
)/)
[/(
2/CD
]/)
was/VBD
conceived/VBN
among/IN
participating/VBG
countries/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
Roadmap/NN
Epigenomics/NNS
Program/NN
was/VBD
fostered/VBN
as/IN
AHEAD/NN
's/POS
suggestion/NN
./.
====================
Finally/RB
the/DT
NIH/NN
Roadmap/NN
Epigenomics/NNS
Program/NN
was/VBD
initiated/VBN
with/IN
the/DT
funding/VBG
of/IN
$/NN
200/CD
million/NN
for/IN
5/CD
years/NNS
from/IN
NIH/NN
[/(
3/CD
]/)
./.
====================
Roadmap/NN
Epigenomics/NNS
aimed/VBD
to/TO
produce/VB
reference/VBP
epigenome/NN
data/NNS
from/IN
a/DT
variety/NN
of/IN
human/JJ
cells/NNS
./.
====================
As/IN
NIH/NN
and/CC
European/JJ
epigenome/JJ
mapping/VBG
activity/NN
was/VBD
commenced/VBN
as/IN
a/DT
locally/RB
scattered/VBN
project/NN
,/,
there/EX
were/VBD
efforts/NNS
to/TO
assemble/JJ
reference/VBP
epigenome/JJ
mapping/VBG
as/IN
an/DT
international/JJ
collaboration/NN
./.
====================
From/IN
2009/CD
,/,
several/JJ
workshops/NNS
were/VBD
held/RB
in/IN
NIH/NN
or/CC
Europe/NN
,/,
and/CC
finally/RB
at/IN
the/DT
2010/CD
Washington/NN
meeting/VBG
,/,
IHEC/NN
was/VBD
officially/RB
born/JJ
./.
====================
The/DT
governance/NN
of/IN
IHEC/NN
====================
Through/IN
February/JJ
2013/CD
,/,
7/CD
member/NN
organizations/countries/NNS
joined/VBN
IHEC/NN
,/,
including/VBG
NIH/NN
Roadmap/NNP
Epigenomics/NNS
,/,
EU/NN
BLUEPRINT/NN
,/,
Germany/NNP
Deutsches/NNS
Epigenom/JJ
Programm/NN
(/(
DEEP/NN
)/)
,/,
Canadian/JJ
Institutes/NNS
for/IN
Health/NN
Research/NN
(/(
CIHR/NN
)/)
,/,
Japan/NNP
Science/NNP
and/CC
Technology/NN
Agency/NN
(/(
JST/NN
)/)
,/,
Korea/NN
KNIH/NN
,/,
and/CC
Italy/RB
./.
====================
Several/JJ
other/JJ
programs/NNS
,/,
such/JJ
as/IN
ENCODE/NN
,/,
England/NN
,/,
France/NN
,/,
and/CC
Singapore/JJ
,/,
expressed/VBD
their/PRP$
intents/NNS
to/TO
join/NN
IHEC/NN
./.
====================
IHEC/NN
consists/VBZ
of/IN
an/DT
Executive/JJ
Committee/NN
(/(
EXEC/NNS
,/,
association/NN
of/IN
funding/VBG
agency/NN
)/)
and/CC
International/JJ
Scientific/JJ
Steering/JJ
Committee/NN
(/(
ISSC/NN
,/,
representatives/VBZ
of/IN
the/DT
member/NN
research/NN
institution/NN
)/)
./.
====================
The/DT
goal/NN
of/IN
IHEC/NN
====================
IHEC/NN
aims/VBZ
at/IN
cataloging/VBG
1,000/CD
human/JJ
reference/NN
epigenomes/NNS
for/IN
the/DT
next/JJ
7/CD
to/TO
10/CD
years/NNS
./.
====================
The/DT
1,000/CD
epigenome/JJ
includes/VBZ
250/CD
types/NNS
of/IN
human/JJ
cells/NNS
,/,
and/CC
10/CD
%/NN
of/IN
the/DT
epigenome/JJ
can/MD
be/VB
mapped/VBN
on/IN
a/DT
model/NN
organism/NN
./.
====================
A/DT
long-term/JJ
objective/NN
of/IN
IHEC/NN
is/VBZ
to/TO
determine/VB
the/DT
extent/NN
to/TO
which/WDT
the/DT
epigenome/JJ
has/VBZ
shaped/VBN
human/JJ
populations/NNS
over/IN
generations/NNS
and/CC
in/IN
response/NN
to/TO
the/DT
environment/NN
and/CC
to/TO
produce/VB
human/JJ
reference/NN
epigenome/JJ
maps/VBZ
for/IN
key/JJ
cellular/JJ
status/NN
relevant/JJ
to/TO
health/NN
and/CC
disease/NN
./.
====================
IHEC/NN
will/MD
focus/VB
on/IN
key/JJ
cellular/JJ
status/NN
,/,
such/JJ
as/IN
stemness/RB
,/,
immortality/NN
,/,
proliferation/NN
,/,
differentiation/NN
,/,
senescence/NN
,/,
and/CC
stress/NN
,/,
thereby/RB
generating/VBG
new/JJ
knowledge/NN
that/DT
will/MD
catalyze/VB
progress/VBP
in/IN
health/NN
research/NN
and/CC
regenerative/JJ
medicine/NN
./.
====================
IHEC/NN
will/MD
coordinate/VB
rapid/JJ
distribution/NN
of/IN
the/DT
data/NNS
to/TO
the/DT
entire/JJ
research/NN
community/NN
with/IN
minimal/JJ
restrictions/NNS
to/TO
accelerate/VB
translation/NN
of/IN
this/DT
new/JJ
knowledge/NN
into/IN
health/NN
and/CC
diseases/NNS
./.
====================
IHEC/NN
also/RB
will/MD
coordinate/VB
the/DT
development/NN
of/IN
common/JJ
bioinformatics/NNS
standards/VBZ
,/,
data/NNS
models/NNS
,/,
and/CC
analytical/JJ
tools/NNS
to/TO
organize/VB
,/,
integrate/JJ
,/,
and/CC
display/VBP
whole/JJ
epigenomic/JJ
data/NNS
generated/VBD
from/IN
this/DT
important/JJ
international/JJ
effort/NN
./.
====================
IHEC/NN
will/MD
set/VB
up/IN
an/DT
efficient/JJ
structure/NN
that/WDT
will/MD
coordinate/VB
this/DT
international/JJ
effort/NN
so/RB
that/IN
the/DT
interest/NN
and/CC
priorities/NNS
of/IN
individual/JJ
participants/NNS
,/,
self-organizing/VBG
consortia/NN
,/,
funding/VBG
agencies/NNS
,/,
and/CC
nations/NNS
are/VBP
addressed/VBN
./.
====================
IHEC/NN
will/MD
encourage/VB
the/DT
minimal/JJ
amount/NN
of/IN
redundancy/NN
between/IN
the/DT
different/JJ
epigenetics/NNS
efforts/NNS
around/IN
the/DT
world/NN
./.
====================
IHEC/NN
will/MD
also/RB
interact/VBP
and/CC
coordinate/VB
its/PRP$
efforts/NNS
with/IN
other/JJ
international/JJ
projects/NNS
,/,
such/JJ
as/IN
ICGC/NN
and/CC
ENCODE/NN
./.
====================
The/DT
secondary/JJ
goal/NN
of/IN
IHEC/NN
is/VBZ
to/TO
catalyze/VB
the/DT
development/NN
of/IN
new/JJ
and/CC
robust/JJ
technologies/NNS
that/IN
will/MD
facilitate/VB
the/DT
characterization/NN
and/CC
functional/JJ
analysis/NN
of/IN
the/DT
epigenome/JJ
in/IN
health/NN
and/CC
diseases/NNS
,/,
thereby/RB
driving/VBG
down/RB
the/DT
costs/NNS
of/IN
epigenome/JJ
mapping/VBG
substantially/RB
,/,
and/CC
to/TO
support/VB
the/DT
dissemination/JJ
of/IN
knowledge/NN
and/CC
standards/IN
related/JJ
to/TO
new/JJ
technologies/NNS
,/,
software/RB
,/,
and/CC
methods/NNS
to/TO
facilitate/VB
data/NNS
integration/NN
and/CC
sharing/VBG
between/IN
epigenetics/NNS
researchers/NNS
around/IN
the/DT
globe/NN
./.
====================
By/IN
the/DT
production/NN
of/IN
1,000/CD
epigenomes/NNS
,/,
IHEC/NN
expects/NNS
that/DT
we/PRP
can/MD
understand/VB
the/DT
key/JJ
cellular/JJ
aspects/NNS
of/IN
250/CD
types/NNS
of/IN
human/JJ
cells/NNS
more/RBR
deeply/RB
./.
====================
Also/RB
,/,
having/VBG
~250/CD
types/NNS
of/IN
reference/NN
epigenomes/NNS
,/,
we/PRP
can/MD
have/VB
the/DT
power/JJ
to/TO
compare/VB
disease/NN
epigenomes/NNS
to/TO
normal/JJ
references/VBZ
,/,
which/WDT
will/MD
help/VB
explain/VB
the/DT
missing/JJ
heritability/NN
of/IN
common/JJ
complex/NN
diseases/NNS
./.
====================
Now/RB
,/,
the/DT
production/NN
of/IN
>/JJR
600/CD
epigenomes/NNS
has/VBZ
been/VBN
planned/VBN
,/,
and/CC
~60/CD
epigenomes/NNS
have/VBP
been/VBN
finished/VBN
[/(
3/CD
,/,
4/CD
]/)
./.
====================
The/DT
role/NN
and/CC
project/VB
of/IN
IHEC/NN
member/NN
institutions/NNS
====================
NIH/NN
Roadmap/NN
Epigenomics/NNS
Program/NN
====================
The/DT
NIH/NN
Roadmap/NN
Epigenomics/NNS
Program/NN
began/VBD
in/IN
2008/CD
and/CC
has/VBZ
a/DT
budget/NN
of/IN
$/NN
200/CD
million/NN
./.
====================
Under/IN
the/DT
cover/RB
of/IN
this/DT
program/NN
,/,
the/DT
NIH/NN
Common/JJ
Fund/JJ
and/CC
NIH/NN
Institutes/NNS
and/CC
Centers/NNS
have/VBP
supported/VBN
a/DT
total/JJ
of/IN
68/CD
grants/NNS
in/IN
the/DT
areas/NNS
of/IN
epigenetic/JJ
technology/NN
development/NN
,/,
identification/NN
of/IN
novel/JJ
epigenetic/JJ
marks/NNS
,/,
reference/VBP
epigenome/JJ
mapping/VBG
,/,
and/CC
disease/NN
epigenomics/NNS
investigations/NNS
./.
====================
The/DT
Reference/NN
Epigenomic/JJ
Mapping/NN
Consortium/NN
,/,
funded/VBD
through/IN
the/DT
Common/JJ
Fund/JJ
's/POS
Roadmap/NN
Epigenomics/NNS
Program/NN
,/,
has/VBZ
been/VBN
generating/VBG
genome-wide/NN
epigenomic/JJ
maps/VBZ
for/IN
a/DT
variety/NN
of/IN
cell/NN
and/CC
tissue/NN
types/NNS
./.
====================
The/DT
majority/NN
of/IN
reference/NN
epigenomes/NNS
that/DT
have/VBP
been/VBN
generated/VBN
contains/VBZ
information/NN
on/IN
epigenetic/JJ
modifications/NNS
,/,
including/VBG
a/DT
core/NN
set/NN
of/IN
histone/NN
marks/NNS
,/,
DNA/NN
methylation/NN
,/,
chromatin/NN
accessibility/NN
,/,
and/CC
gene/NN
expression/NN
information/NN
./.
====================
A/DT
subset/NN
of/IN
reference/NN
epigenomes/NNS
also/RB
contains/VBZ
an/DT
expanded/VBN
set/NN
of/IN
20/CD
additional/JJ
histone/NN
modifications/NNS
[/(
5/CD
]/)
./.
====================
Data/NNS
for/IN
52/CD
complete/JJ
and/CC
partial/JJ
epigenome/JJ
datasets/NNS
for/IN
varieties/NNS
of/IN
normal/JJ
human/JJ
cells/NNS
and/CC
tissues/NNS
are/VBP
available/JJ
./.
====================
Epigenomes/NNS
were/VBD
mapped/VBN
on/IN
embryonic/JJ
stem/NN
(/(
ES/NNS
)/)
cells/NNS
,/,
ES/NN
cell/NN
derivatives/NNS
,/,
induced/VBD
pluripotent/JJ
stem/NN
cells/NNS
,/,
multiple/JJ
fetal/JJ
tissues/NNS
,/,
several/JJ
varieties/NNS
of/IN
blood/NN
and/CC
immune/JJ
cells/NNS
,/,
breast/NN
cell/NN
types/NNS
,/,
placenta/NN
,/,
and/CC
solid/JJ
tissues/NNS
(/(
e.g./FW
,/,
adipose/DT
,/,
gastrointestinal/JJ
tract/VBP
,/,
skin/NN
,/,
and/CC
brain/NN
)/)
./.
====================
Roadmap/NN
Epigenomics/NNS
plans/NNS
to/TO
complete/JJ
~100/NN
additional/JJ
epigenomes/NNS
by/IN
the/DT
end/NN
of/IN
the/DT
program/NN
[/(
3/CD
,/,
4/CD
]/)
./.
====================
European/NN
Union/NN
:/:
BLUEPRINT/NN
====================
The/DT
BLUEPRINT/NN
consortium/NN
,/,
consisting/VBG
of/IN
41/CD
leading/VBG
European/NN
universities/NNS
,/,
research/NN
institutes/NNS
,/,
and/CC
industry/NN
entrepreneurs/VBZ
,/,
was/VBD
selected/VBN
for/IN
funding/VBG
in/IN
early/JJ
2011/CD
./.
====================
The/DT
project/JJ
officially/RB
started/VBD
on/IN
October/NN
1/CD
,/,
2011/CD
and/CC
will/MD
run/VB
for/IN
4-5/CD
years/NNS
./.
====================
BLUEPRINT/NN
has/VBZ
an/DT
overall/JJ
budget/NN
of/IN
39.4/CD
million/NN
€/CD
,/,
for/IN
which/WDT
it/PRP
receives/VBZ
30/CD
million/NN
€/CD
in/IN
funding/VBG
from/IN
the/DT
European/JJ
Commission/NN
./.
====================
BLUEPRINT/NN
aims/VBZ
to/TO
generate/VB
at/IN
least/JJS
100/CD
reference/NN
epigenomes/NNS
on/IN
blood/NN
lineage/NN
(/(
hematopoietic/JJ
)/)
cells/NNS
from/IN
healthy/JJ
individuals/NNS
and/CC
on/IN
their/PRP$
malignant/JJ
leukemic/JJ
counterparts/NNS
./.
====================
The/DT
BLUEPRINT/NN
reference/VBP
epigenome/JJ
will/MD
cover/RB
the/DT
IHEC/NN
epigenome/JJ
set/NN
and/CC
further/RB
expand/CC
up/IN
to/TO
19/CD
'marks/NNS
,/,
'/``
called/VBN
a/DT
'BLUEPRINT/JJ
set/NN
'/``
(/(
including/VBG
H3K79me3/NN
,/,
H3K9/14ac/NN
,/,
H4K20me3/NNP
,/,
H4pan/H4K16ac/JJ
,/,
H2AZ-ac/JJ
,/,
H2AZ/NN
,/,
p300/NN
,/,
and/CC
RNA/NN
PolII/NN
)/)
[/(
4/CD
,/,
6/CD
]/)
./.
====================
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
KNIH/NN
)/)
Metabolic/JJ
Epigenome/JJ
Project/NN
====================
The/DT
project/JJ
proposal/JJ
from/IN
KNIH/NN
,/,
the/DT
Center/JJ
for/IN
Genome/NN
Sciences/NNS
,/,
Epigenome/JJ
Mapping/NN
Center/NN
(/(
EMC/NN
)/)
,/,
5/CD
chronic/JJ
disease-related/JJ
hospital/JJ
,/,
were/VBD
finally/RB
selected/VBN
for/IN
funding/VBG
during/IN
the/DT
period/NN
of/IN
2012-2013/CD
./.
====================
The/DT
project/JJ
officially/RB
started/VBD
on/IN
January/NN
2012/CD
and/CC
will/MD
run/VB
for/IN
>/JJR
5/CD
years/NNS
./.
====================
KNIH/NN
has/VBZ
an/DT
overall/JJ
budget/NN
of/IN
$/NN
10.9/CD
million/NN
for/IN
5/CD
years/NNS
./.
====================
Participating/JJ
clinical/JJ
institutions/NNS
were/VBD
chosen/RB
from/IN
Samsung/JJ
Medical/JJ
Center/JJ
(/(
heart/NN
tissue/NN
and/CC
cardiomyopathy/JJ
)/)
,/,
Hanyang/NNP
University/JJ
Hospital/JJ
(/(
blood/NN
,/,
synoviocyte/NN
cell/NN
,/,
and/CC
rheumatoid/JJ
arthritis/NN
)/)
,/,
Asan/NNP
Medical/JJ
Center/JJ
(/(
pancreatic/JJ
tissue/NN
,/,
adipose/DT
tissue/NN
,/,
T2D/NN
,/,
and/CC
obesity/NN
)/)
,/,
and/CC
Seoul/JJ
National/JJ
University/JJ
Hospital/JJ
(/(
kidney/NN
tissue/NN
and/CC
chronic/JJ
kidney/NN
disease/NN
)/)
./.
====================
KNIH/NN
aims/VBZ
to/TO
generate/VB
at/IN
least/JJS
50/CD
reference/VBP
epigenomes/NNS
and/CC
study/NN
them/PRP
to/TO
advance/VB
and/CC
exploit/VBP
knowledge/NN
of/IN
the/DT
underlying/VBG
biological/JJ
processes/NNS
and/CC
mechanisms/NNS
in/IN
health/NN
and/CC
disease/NN
./.
====================
KNIH/NN
will/MD
focus/VB
on/IN
50/CD
distinct/JJ
types/NNS
of/IN
homogenous/JJ
cells/NNS
of/IN
tissues/NNS
related/JJ
to/TO
5/CD
chronic/JJ
diseases/NNS
(/(
heart/NN
failure/NN
,/,
autoimmune/JJ
diseases/NNS
,/,
diabetes/VBZ
,/,
obesity/NN
,/,
and/CC
chronic/JJ
kidney/NN
disease/NN
)/)
from/IN
normal/JJ
and/CC
disease/NN
tissue/NN
,/,
mainly/RB
obtained/VBN
by/IN
tissue/NN
removal/NN
or/CC
transplantation/NN
./.
====================
The/DT
Korea/NN
reference/RB
epigenome/DT
will/MD
entail/VBP
the/DT
analysis/NN
of/IN
12/CD
'marks/NNS
'/``
;/:
an/DT
IHEC/NN
CORE/NN
set/NN
:/:
DNAme/JJ
,/,
H3K4me3/NNP
,/,
H3K4me1/NNP
,/,
H3K9me3/NNP
,/,
H3K27me3/NNP
,/,
H3K27ac/NNP
,/,
H3K36me3/NNP
,/,
RNA-seq/NNP
,/,
and/CC
RNA-chromatin/NN
immunoprecipitation/NN
(/(
RNA-ChIP/NN
)/)
,/,
DNaseI/NN
hypersensitivity/NN
,/,
formaldehyde-assisted/VBN
isolation/NN
of/IN
regulatory/JJ
elements/NNS
(/(
FAIRE/NN
)/)
-seq/JJ
,/,
chromatin/NN
interaction/NN
analysis/NN
using/VBG
paired/JJ
end/NN
tags/NNS
(/(
CHIA-PET/NN
)/)
,/,
and/CC
miRNA-seq/JJ
(/(
Tables/NNS
2/CD
and/CC
3/CD
)/)
[/(
4/CD
]/)
./.
====================
Japan/NN
Science/NN
and/CC
Technology/NN
Agency/NN
====================
JST/NN
's/POS
leading/VBG
program/NN
is/VBZ
the/DT
Core/NN
Research/NN
for/IN
Evolutional/JJ
Science/NNP
and/CC
Technology/NN
(/(
CREST/NN
)/)
's/POS
disease/NN
epigenome/NN
project/VB
./.
====================
In/IN
2011/CD
,/,
JST/NN
started/VBD
a/DT
research/NN
area/NN
of/IN
``/NN
Development/NN
of/IN
fundamental/JJ
technologies/NNS
for/IN
diagnosis/NN
and/CC
therapy/NN
based/VBN
upon/IN
epigenome/JJ
analysis/NN
(/(
disease/NN
epigenome/NN
)/)
./.
''/CD
====================
This/DT
research/NN
area/NN
focuses/VBZ
on/IN
the/DT
IHEC/NN
projects/NNS
and/CC
various/JJ
epigenome/JJ
analyses/NNS
related/JJ
to/TO
diseases/NNS
and/CC
stem/NN
cells/NNS
./.
====================
In/IN
2011-2012/CD
,/,
10/CD
projects/NNS
were/VBD
awarded/VBN
,/,
including/VBG
3/CD
IHEC/NN
projects/NNS
./.
====================
JST/NN
'/``
proposal/JJ
focused/VBN
the/DT
epithelial/JJ
cells/NNS
of/IN
the/DT
digestive/JJ
system/NN
(/(
stomach/DT
,/,
colon/NN
,/,
and/CC
liver/NN
)/)
,/,
the/DT
vascular/JJ
endothelial/JJ
cells/NNS
,/,
and/CC
the/DT
epigenome/JJ
in/IN
germ/JJ
cells/NNS
and/CC
reproductive/JJ
tissue/NN
(/(
placental/JJ
cell/NN
,/,
cytotrophoblast/JJ
,/,
syncytiotrophoblast/JJ
,/,
endometrial/JJ
cells/NNS
,/,
basal/JJ
layer/NN
cells/NNS
,/,
proliferative/JJ
functional/JJ
layer/NN
cells/NNS
,/,
and/CC
secretary/JJ
functional/JJ
layer/NN
cells/NNS
)/)
(/(
Tables/NNS
2/CD
and/CC
3/CD
)/)
[/(
4/CD
]/)
./.
====================
The/DT
Italian/JJ
epigenome/NN
program/NN
====================
The/DT
Italian/JJ
epigenome/NN
program/NN
involves/VBZ
two/CD
initiatives/VBZ
:/:
the/DT
Milan/NN
Genomic/JJ
Initiative/JJ
(/(
MGI/NN
)/)
and/CC
the/DT
Italian/JJ
Flagship/NN
Project/NN
EPIGEN/NN
./.
====================
The/DT
MGI/NN
was/VBD
started/VBN
in/IN
2011/CD
as/IN
a/DT
joint/NN
operation/NN
among/IN
Istituto/JJ
Europeo/NN
di/JJ
Oncologia/FW
(/(
IEO/NN
)/)
,/,
Istituto/NNP
Italiano/DT
di/JJ
Technologia/NN
(/(
IIT/NN
)/)
,/,
and/CC
Istituto/JJ
FIRC/NN
di/JJ
Oncologia/FW
Molecolare/NNP
(/(
IFOM/NN
)/)
and/CC
is/VBZ
located/JJ
at/IN
the/DT
IFOM-IEO/NN
campus/FW
in/IN
Milan/JJ
,/,
a/DT
multi-institutional/JJ
biomedical/JJ
research/NN
area/NN
hosting/VBG
over/IN
500/CD
scientists/NNS
./.
====================
The/DT
MGI/NN
includes/VBZ
16/CD
independent/JJ
research-groups/NNS
in/IN
the/DT
field/NN
of/IN
epigenetics/NNS
./.
====================
The/DT
three/CD
institutions/NNS
are/VBP
committed/VBN
to/TO
5-year/JJ
support/VBP
of/IN
the/DT
``/NN
Center/NN
of/IN
Genomic/JJ
Science/NNP
''/CD
for/IN
a/DT
total/JJ
of/IN
~10/CD
million/NN
€/CD
./.
====================
EPIGEN/NN
was/VBD
launched/VBN
by/IN
the/DT
Italian/JJ
Ministry/NN
of/IN
Research/NN
and/CC
started/VBD
in/IN
January/NN
2012/CD
./.
====================
It/PRP
includes/VBZ
25/CD
independent/JJ
groups/NNS
./.
====================
EPIGEN/NN
is/VBZ
supported/VBN
by/IN
funding/VBG
of/IN
30/CD
million/NN
€/CD
for/IN
4/CD
years/NNS
./.
====================
MGI/NN
has/VBZ
been/VBN
a/DT
member/NN
of/IN
IHEC/NN
since/IN
2011/CD
,/,
and/CC
EPIGEN/NN
is/VBZ
currently/RB
following/VBG
the/DT
required/VBN
procedures/NNS
with/IN
the/DT
Italian/JJ
Ministry/NN
of/IN
Research/NN
for/IN
formal/JJ
application/NN
to/TO
IHEC/NN
./.
====================
In/IN
parallel/NN
,/,
both/CC
initiatives/VBZ
are/VBP
working/VBG
on/IN
a/DT
coordination/NN
plan/NN
with/IN
the/DT
goal/NN
of/IN
joint/NN
participation/NN
to/TO
IHEC/NN
./.
====================
MGI/NN
expects/VBZ
to/TO
provide/VB
50/CD
reference/VBP
epigenomes/NNS
,/,
completed/VBN
to/TO
IHEC/NN
standards/VBZ
,/,
over/IN
the/DT
next/JJ
5/CD
years/NNS
,/,
including/VBG
cells/NNS
from/IN
hematopoietic/JJ
,/,
mammary/JJ
,/,
adipose/DT
,/,
liver/NN
,/,
and/CC
neural/JJ
tissues/NNS
./.
====================
Epigen/JJ
focuses/VBZ
on/IN
research/NN
projects/NNS
,/,
such/JJ
as/IN
the/DT
role/NN
of/IN
chromatin/NN
structure/NN
,/,
DNA/NN
methylation/NN
,/,
and/CC
nuclear/JJ
architecture/NN
in/IN
epigenetic/JJ
regulation/NN
and/CC
epigenetic/JJ
control/JJ
through/IN
the/DT
noncoding/JJ
component/NN
of/IN
the/DT
genome/NN
:/:
structure/NN
and/CC
dynamics/NNS
,/,
epigenetic/JJ
control/JJ
of/IN
cellular/JJ
identity/NN
and/CC
human/JJ
pathologies/NNS
,/,
epidrugs/NNS
for/IN
therapeutic/JJ
use/NN
,/,
and/CC
plant/JJ
epigenomics/NNS
[/(
4/CD
]/)
./.
====================
Germany/DT
epigenome/NN
project/NN
:/:
DEEP/NN
====================
DEEP/NN
's/POS
funding/VBG
is/VBZ
approx/RB
./.
====================
16/CD
million/NN
€/CD
by/IN
the/DT
German/JJ
Federal/JJ
Ministry/NN
of/IN
Education/NN
and/CC
Research/NN
(/(
BMBF/NN
)/)
,/,
from/IN
2012/CD
to/TO
2017/CD
./.
====================
DEEP/NN
creates/VBZ
an/DT
interdisciplinary/JJ
research/NN
platform/NN
of/IN
17/CD
subprojects/NNS
,/,
linking/VBG
21/CD
epigenomic/JJ
mapping/NN
and/CC
functional/JJ
analysis/NN
groups/NNS
across/IN
Germany/NNP
./.
====================
As/IN
the/DT
German/NNP
contribution/NN
to/TO
IHEC/NN
,/,
DEEP/NN
plans/NNS
to/TO
produce/VB
and/CC
functionally/RB
interpret/VB
70/CD
reference/NN
epigenomes/NNS
of/IN
selected/VBN
human/JJ
(/(
and/CC
some/DT
murine/JJ
)/)
cells/NNS
and/CC
tissues/NNS
./.
====================
DEEP/NN
will/MD
focus/VB
on/IN
cell/NN
types/NNS
connected/VBD
to/TO
metabolic/JJ
diseases/NNS
,/,
such/JJ
as/IN
steatosis/RB
(/(
hepatocytes/NNS
and/CC
Kupffer/NNP
cells/NNS
)/)
and/CC
obesity/NN
(/(
adipocytes/NNS
[/(
small/large/JJ
,/,
visceral/subcutaneous/JJ
]/)
,/,
monocytes/NNS
,/,
and/CC
macrophages/NNS
)/)
,/,
as/IN
well/RB
as/IN
inflammatory/JJ
diseases/NNS
,/,
such/JJ
as/IN
Crohn/NN
disease/NN
(/(
mucosa/NN
,/,
macrophages/NNS
,/,
and/CC
T-memory/effector/NN
cells/NNS
)/)
and/CC
rheumatoid/JJ
arthritis/NN
(/(
fibroblasts/NNS
,/,
macrophages/NNS
,/,
and/CC
T-memory/effector/NN
cells/NNS
)/)
(/(
Tables/NNS
2/CD
and/CC
3/CD
)/)
[/(
6/CD
]/)
./.
====================
Canada/NN
:/:
The/DT
Canadian/JJ
Epigenetics/NNS
,/,
Environment/JJ
and/CC
Health/NN
Research/NN
Consortium/NN
(/(
CEEHRC/NN
)/)
====================
In/IN
2011/CD
,/,
the/DT
CIHR/NN
established/VBN
a/DT
national/JJ
collaborative/JJ
research/NN
funding/VBG
strategy/NN
to/TO
coordinate/VB
epigenetics/NNS
research/NN
in/IN
Canada/NN
,/,
CEEHRC/NN
./.
====================
The/DT
budget/NN
of/IN
the/DT
CEEHRC/NN
is/VBZ
$/CD
50/CD
million/NN
over/IN
7/CD
years/NNS
./.
====================
CEEHRC/NN
is/VBZ
supporting/VBG
two/CD
EMCs/NNS
and/CC
two/CD
Epigenomic/JJ
Data/NNS
Coordination/NN
Centers/NNS
(/(
EDCCs/NNS
)/)
,/,
for/IN
a/DT
total/JJ
investment/JJ
of/IN
$/NN
15/CD
million/NN
over/IN
5/CD
years/NNS
./.
====================
The/DT
CEEHRC-funded/JJ
EMCs/NNS
are/VBP
the/DT
Center/JJ
for/IN
Epigenomic/JJ
Mapping/NN
Technologies/NNS
(/(
CEMT/NN
)/)
,/,
at/IN
the/DT
University/JJ
of/IN
British/JJ
Columbia/BC/NN
Cancer/NN
Agency/NN
,/,
and/CC
the/DT
Multidimensional/JJ
Epigenomics/NNS
Mapping/NN
Center/NN
at/IN
McGill/NNP
(/(
MEMCM/NN
)/)
,/,
at/IN
McGill/NNP
University/NN
./.
====================
The/DT
funded/JJ
EDCCs/NNS
are/VBP
at/IN
Simon/JJ
Fraser/NN
University/BC/JJ
Cancer/NN
Agency/NN
and/CC
at/IN
McGill/NNP
University/NN
./.
====================
The/DT
CEMT/NN
group/NN
is/VBZ
focusing/VBG
on/IN
a/DT
number/NN
of/IN
cancer/NN
and/CC
stem/NN
cell/NN
types/NNS
,/,
including/VBG
studies/NNS
on/IN
peripheral/JJ
and/CC
lymphoid/JJ
B-cells/NNS
,/,
T-lymphocytes/NNS
,/,
primitive/JJ
hematopoietic/JJ
cells/NNS
,/,
and/CC
patient-derived/JJ
induced/VBD
pluoripotent/JJ
stem/NN
cell/NN
,/,
as/IN
well/RB
as/IN
thyroid/NN
cells/NNS
and/CC
mammary/JJ
,/,
endometrial/JJ
,/,
fallopian/JJ
,/,
and/CC
colonic/JJ
epithelium/NN
./.
====================
The/DT
MEMCM/NN
group/NN
has/VBZ
three/CD
initial/JJ
focus/NN
areas/IN
:/:
autoimmune/JJ
and/CC
inflammatory/JJ
disease/NN
(/(
using/VBG
various/JJ
blood/NN
cell/NN
types/NNS
)/)
,/,
cardio-metabolic/JJ
disease/NN
(/(
including/VBG
cardiac/JJ
and/CC
skeletal/JJ
muscle/NN
,/,
liver/RB
,/,
adipose/DT
tissue/NN
,/,
and/CC
pancreatic/JJ
islets/NNS
)/)
,/,
and/CC
neuropsychiatric/JJ
disease/NN
(/(
including/VBG
targeted/VBN
brain/NN
areas/NNS
in/IN
post/JJ
mortem/RBR
suicide/JJ
human/JJ
tissue/NN
,/,
and/CC
animal/JJ
models/NNS
of/IN
hypothalamus/pituitary/adrenal/JJ
axis/NN
dysfunction/NN
)/)
./.
====================
In/IN
addition/NN
,/,
MEMCM/NN
specifically/RB
addresses/VBZ
population/NN
variations/NNS
in/IN
epigenomes/NNS
within/IN
these/DT
focus/NN
areas/NNS
./.
====================
The/DT
EMCs/NNS
together/RB
expect/VB
to/TO
provide/VB
200/CD
reference/VBP
epigenomes/NNS
,/,
completed/VBN
to/TO
IHEC/NN
standards/NNS
,/,
over/IN
the/DT
next/JJ
5/CD
years/NNS
(/(
Tables/NNS
2/CD
and/CC
3/CD
)/)
[/(
6/CD
]/)
./.
====================
The/DT
standard/JJ
and/CC
definition/NN
of/IN
IHEC/NN
epigenome/NN
project/NN
====================
Tissue/NN
and/CC
cell/NN
standard/JJ
====================
The/DT
normal/JJ
phenotype/NN
of/IN
a/DT
sample/JJ
should/MD
be/VB
macroscopically/RB
and/CC
microscopically/RB
confirmed/VBD
by/IN
at/IN
least/JJS
two/CD
pathologists/NNS
./.
====================
To/TO
monitor/VB
the/DT
cell/NN
quality/NN
,/,
RNA/NN
quality/NN
should/MD
be/VB
assessed/VBN
by/IN
RNA/NN
integrity/NN
number/NN
(/(
RIN/NN
)/)
./.
====================
The/DT
value/NN
is/VBZ
expected/VBN
to/TO
exceed/VB
8/CD
(/(
cell/NN
lines/NNS
)/)
or/CC
4/CD
(/(
cells/NNS
isolated/VBN
from/IN
primary/JJ
tissues/NNS
)/)
and/CC
should/MD
be/VB
described/VBN
as/IN
the/DT
sample/NN
information/NN
./.
====================
The/DT
purity/NN
of/IN
cells/NNS
whose/WP$
epigenome/JJ
is/VBZ
analyzed/VBN
must/MD
be/VB
assessed/VBN
by/IN
immunocytochemistry/NN
,/,
cell/NN
sorting/NN
,/,
or/CC
other/JJ
methods/NNS
./.
====================
The/DT
cell/NN
purity/NN
is/VBZ
expected/VBN
to/TO
exceed/VB
90/CD
%/NN
./.
====================
However/RB
,/,
if/IN
this/DT
is/VBZ
practically/RB
difficult/JJ
,/,
the/DT
purity/NN
of/IN
a/DT
sample/JJ
should/MD
be/VB
described/VBN
as/IN
the/DT
sample/NN
information/NN
./.
====================
For/IN
optimal/JJ
ChIP/NN
results/NNS
,/,
it/PRP
is/VBZ
recommended/VBN
to/TO
use/VB
more/RBR
than/IN
1/CD
×/NN
106/CD
cells/NNS
per/FW
chromatin/NN
immunoprecipitation/NN
./.
====================
Definition/NN
of/IN
IHEC/NN
epigenome/NN
set/NN
====================
The/DT
IHEC/NN
epigenome/DT
set/RB
consists/VBZ
of/IN
methylome/JJ
(/(
Bisulfite-seq/NNP
[/(
required/VBN
]/)
,/,
methylated/VBN
DNA/NN
immunoprecipitation-seq/NN
[/(
MeDIP-seq/NNP
]/)
,/,
methylation-sensitive/JJ
restriction/NN
enzyme-seq/NN
[/(
MRE-seq/NNP
]/)
,/,
reduced/VBD
representation/NN
bisulphite-seq/IN
[/(
RRBS/NN
]/)
,/,
methylation/NN
capturing-seq/RB
[/(
methylCap-seq/JJ
]/)
[/(
any/DT
of/IN
4/CD
required/VBN
on/IN
Roadmap/NNP
]/)
)/)
,/,
RNA/NN
(/(
RNA-seq/NNP
,/,
RNA-ChIP/NNP
[/(
required/VBN
to/TO
Roadmap/NNP
]/)
,/,
smRNA-seq/RB
[/(
optional/JJ
]/)
)/)
,/,
ChIP-seq/NNP
[/(
input/RB
,/,
H3K27me3/NNP
,/,
H3K36me3/NNP
,/,
H3K4me1/NNP
,/,
H3K4me3/NNP
,/,
H3K27ac/NNP
,/,
H3K9me3/NNP
]/)
,/,
and/CC
chromatin/NN
accessibility/NN
(/(
DNaseI/NN
hypersensitivity/NN
,/,
digital/JJ
genomic/JJ
footprinting/NN
,/,
FAIRE-seq/NNP
[/(
any/DT
3/LS
optional/JJ
]/)
)/)
(/(
Table/JJ
3/LS
)/)
[/(
6/CD
]/)
./.
====================
Definition/NN
of/IN
IHEC/NN
metadata/NNS
====================
Metadata/NNS
standards/NNS
are/VBP
the/DT
data-related/JJ
information/NN
required/VBN
for/IN
data/NNS
integration/NN
produced/VBN
from/IN
individual/JJ
IHEC/NN
institutions/NNS
./.
====================
It/PRP
consists/VBZ
of/IN
3/CD
components/NNS
:/:
data/NNS
standards/VBZ
,/,
assay/NN
standards/VBZ
,/,
and/CC
programmatic/JJ
interoperability/NN
and/CC
programming/VBG
interfaces/VBZ
,/,
such/JJ
as/IN
Representational/JJ
State/NN
Transfer/NN
Application/NN
Programing/JJ
Interfaces/NNS
(/(
REST/NN
APIs/NNS
)/)
,/,
allowing/VBG
programs/NNS
(/(
apps/NNS
)/)
to/TO
pull/JJ
data/NNS
and/CC
metadata/NNS
together/RB
from/IN
various/JJ
sources/NNS
across/IN
the/DT
web/NN
./.
====================
Metadata/NNS
standards/VBZ
allow/VBP
computer/NN
programs/NNS
and/CC
end/NN
users/NNS
to/TO
access/VB
essential/JJ
information/NN
about/IN
performed/VBN
experiments/NNS
,/,
such/JJ
as/IN
the/DT
information/NN
about/IN
assays/NNS
,/,
samples/NNS
assayed/VBN
,/,
and/CC
algorithms/NNS
used/VBN
to/TO
produce/VB
interpretable/JJ
data/NNS
./.
====================
In/IN
the/DT
preparatory/JJ
stage/NN
,/,
the/DT
project/JJ
was/VBD
to/TO
complete/JJ
a/DT
case/NN
study/NN
in/IN
data/NNS
and/CC
software/JJ
integration/NN
using/VBG
the/DT
Genboree/JJ
system/NN
[/(
6/CD
]/)
./.
====================
Several/JJ
standards/NNS
have/VBP
yet/RB
to/TO
be/VB
defined/VBN
,/,
particularly/RB
controlled/VBN
vocabularies/NNS
and/CC
ontologies/NNS
for/IN
important/JJ
data/NNS
elements/NNS
,/,
such/JJ
as/IN
sample/JJ
types/NNS
,/,
disease/NN
conditions/NNS
,/,
and/CC
phenotypes/NNS
[/(
6/CD
]/)
./.
====================
Definition/NN
of/IN
IHEC/NN
data/NNS
ecosystem/VBP
standard/JJ
====================
The/DT
IHEC/NN
data/NNS
ecosystem/VBP
project/VB
is/VBZ
to/TO
provide/VB
the/DT
infrastructure/JJ
of/IN
data/NNS
repositories/VBZ
and/CC
resources/VBZ
that/DT
enable/VBP
data/NNS
sharing/VBG
by/IN
working/VBG
together/RB
for/IN
the/DT
collection/NN
,/,
processing/NN
,/,
storage/NN
,/,
and/CC
distribution/NN
of/IN
data/NNS
from/IN
IHEC/NN
./.
====================
Data/NNS
are/VBP
normally/RB
submitted/VBN
to/TO
the/DT
central/JJ
data/NNS
repository/JJ
site/NN
by/IN
individual/JJ
data/NNS
producers/NNS
./.
====================
Processed/VBN
IHEC/NN
data/NNS
,/,
such/JJ
as/IN
peak/NN
calls/NNS
and/CC
epigenome/JJ
maps/VBZ
,/,
may/MD
not/RB
be/VB
deposited/VBN
in/IN
a/DT
central/JJ
data/NNS
repository/JJ
and/CC
may/MD
be/VB
only/RB
made/VBD
available/JJ
directly/RB
by/IN
the/DT
data/NNS
distribution/NN
component/NN
(/(
local/JJ
)/)
of/IN
the/DT
data/NNS
ecosystem/VBP
./.
====================
There/EX
is/VBZ
value/NN
in/IN
distributing/VBG
both/CC
the/DT
raw/NN
and/CC
processed/VBN
data/NNS
,/,
and/CC
both/CC
will/MD
be/VB
provided/VBN
./.
====================
A/DT
virtual/JJ
data/NNS
integration/NN
center/NN
will/MD
be/VB
conceived/VBN
in/IN
developing/VBG
an/DT
IHEC/NN
data/NNS
sharing/VBG
system/NN
,/,
and/CC
a/DT
joint/NN
project/VB
with/IN
a/DT
metadata/JJ
standard/JJ
project/JJ
will/MD
be/VB
done/VBN
in/IN
the/DT
near/JJ
future/JJ
[/(
6/CD
,/,
7/CD
]/)
./.
====================
Although/IN
the/DT
international/JJ
consortium/NN
is/VBZ
now/RB
in/IN
good/JJ
shape/NN
,/,
it/PRP
still/RB
has/VBZ
several/JJ
limitations/NNS
./.
====================
As/IN
the/DT
IHEC/NN
aims/VBZ
at/IN
producing/VBG
1,000/CD
epigenomes/NNS
from/IN
~250/CD
human/JJ
cell/NN
types/NNS
,/,
there/EX
is/VBZ
a/DT
limitation/NN
on/IN
tissue/NN
or/CC
cell/NN
availability/NN
./.
====================
Epigenome/DT
production/NN
from/IN
extremely/RB
hard-to-get/VBP
cells/NNS
or/CC
tissues/NNS
seems/VBZ
impossible/JJ
to/TO
accomplish/VB
and/CC
looks/NNS
even/RB
unnecessary/JJ
./.
====================
To/TO
overcome/VB
this/DT
limitation/NN
,/,
there/EX
are/VBP
some/DT
efforts/NNS
to/TO
perform/VB
ChIP-seq/NN
with/IN
fewer/JJR
than/IN
~1,000/CD
cells/NNS
and/CC
to/TO
perform/VB
single-cell-level/JJ
epigenome/JJ
analysis/NN
[/(
14/CD
]/)
./.
====================
Also/RB
,/,
there/EX
is/VBZ
an/DT
individual/JJ
variation/NN
issue/NN
:/:
as/IN
epigenomes/NNS
differ/VBP
by/IN
individual/JJ
,/,
age/NN
,/,
cell/NN
type/NN
,/,
and/CC
developmental/JJ
stage/NN
,/,
it/PRP
will/MD
be/VB
very/RB
hard/RB
to/TO
determine/VB
the/DT
real/JJ
reference/VBP
data/NNS
among/IN
numerous/JJ
epigenomic/JJ
states/NNS
./.
====================
It/PRP
is/VBZ
required/VBN
to/TO
determine/VB
the/DT
exact/JJ
reference/NN
epigenome/NN
more/RBR
precisely/RB
./.
====================
Moreover/RB
,/,
overlapping/VBG
target/NN
tissues/NNS
among/IN
member/NN
institutions/NNS
is/VBZ
a/DT
limitation/NN
./.
====================
Cell/NN
types/NNS
,/,
such/JJ
as/IN
blood/NN
and/CC
adipocyte/NN
,/,
that/DT
easy/RB
to/TO
get/VB
seem/VBP
to/TO
be/VB
popular/JJ
targets/NNS
in/IN
every/DT
IHEC/NN
member/NN
and/CC
should/MD
be/VB
coordinated/VBN
in/IN
a/DT
central/JJ
way/NN
to/TO
foster/RBR
synergy/NN
from/IN
each/DT
mapping/VBG
activity/NN
./.
====================
Another/DT
issue/NN
is/VBZ
a/DT
limitation/NN
of/IN
international/JJ
collaboration/NN
./.
====================
As/IN
all/DT
funds/VBZ
are/VBP
controlled/VBN
by/IN
an/DT
individual/JJ
institution/NN
's/POS
decision/NN
,/,
drawing/VBG
a/DT
concrete/JJ
conclusion/NN
on/IN
a/DT
specific/JJ
point/NN
is/VBZ
expected/VBN
to/TO
be/VB
a/DT
time-consuming/JJ
process/NN
./.
====================
There/EX
is/VBZ
newly/RB
emerging/VBG
technology/NN
on/IN
targeting/VBG
several/JJ
novel/JJ
epigenome/NN
sets/NNS
,/,
such/JJ
as/IN
carboxyl/JJ
methylation/NN
[/(
15/CD
]/)
,/,
m6A/NN
RNA/NN
methylation/NN
[/(
16/CD
]/)
,/,
hydroxyl/NN
methylation/NN
[/(
8/CD
]/)
,/,
and/CC
3D/NN
chromosomal/JJ
interaction/NN
[/(
17/CD
]/)
./.
====================
Also/RB
,/,
collaboration/NN
with/IN
the/DT
ENCODE/NN
project/VB
on/IN
transcription/NN
factor/NN
binding/NN
site/NN
profiling/VBG
should/MD
be/VB
actively/RB
considered/VBN
in/IN
near/JJ
future/JJ
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Furthermore/RB
,/,
in/IN
the/DT
next/JJ
phase/NN
of/IN
IHEC/NN
,/,
disease/NN
epigenome/NN
should/MD
be/VB
considered/VBN
./.
====================
Actually/RB
,/,
all/DT
7/CD
member/NN
countries/NNS
are/VBP
focusing/VBG
on/IN
disease/NN
relatedness/NN
actively/RB
,/,
such/JJ
as/IN
the/DT
metabolic/JJ
epigenome/NN
,/,
hematopoietic/JJ
epigenome/JJ
,/,
and/CC
digestive/JJ
organ/NN
disorders/NNS
,/,
but/CC
more/RBR
active/JJ
engagement/NN
and/CC
control/NN
should/MD
be/VB
anticipated/JJ
in/IN
each/DT
project/VB
's/POS
detailed/JJ
goals/NNS
./.
====================
Extension/NN
to/TO
epigenome/JJ
wide/JJ
association/NN
study/NN
should/MD
also/RB
be/VB
considered/VBN
to/TO
increase/VB
the/DT
clinical/JJ
importance/NN
of/IN
IHEC/NN
's/POS
reference/NN
mapping/NN
efforts/NNS
[/(
9/CD
]/)
./.
====================
Perspectives/NNS
of/IN
epigenome/JJ
research/NN
./.
====================
MeDIP/DT
,/,
methylated/VBN
DNA/NN
immunoprecipitation-sequencing/NN
;/:
MIRAseq/NNP
,/,
methylated/VBN
CpG/NN
island/NN
recovery/RB
assay-sequencing/VBG
;/:
iPS/RB
,/,
induced/VBD
pluoripetent/JJ
stem/NN
cell/NN
;/:
mC-seq/RB
,/,
methylated/VBN
cytosine-sequencing/JJ
;/:
CHIA-PET/NNP
,/,
chromatin/NN
interaction/NN
analysis/NN
using/VBG
paired/JJ
end/NN
tags/NNS
;/:
T2D/NNP
,/,
type/NN
2/CD
diabetes/VBZ
;/:
GWAS/NNP
,/,
genome-wide/RB
association/NN
study/RB
;/:
ENCODE/NNP
,/,
Encyclopedia/NN
of/IN
DNA/NN
Element/NN
;/:
EWAS/NNP
,/,
epigenomewide/JJ
association/NN
study/RB
;/:
hmC-seq/RB
,/,
hydroxyl/NN
methyl/JJ
cytosine-sequencing/JJ
;/:
IDH/NNP
,/,
isocitrate/RB
dehydrogenase/NN
;/:
IHEC/NN
,/,
International/NNP
Human/JJ
Epigenome/JJ
Consortium/NN
./.
====================
Major/JJ
international/JJ
efforts/NNS
after/IN
the/DT
Human/JJ
Genome/NN
Project/NN
(/(
HGP/NN
)/)
completion/NN
in/IN
2003/CD
====================
1,000/CD
Epigenome/JJ
production/NN
scheme/VBP
====================
Definition/NN
of/IN
International/JJ
Human/JJ
Epigenome/JJ
Consortium/NN
(/(
IHEC/NN
)/)
epigenome/NN
set/NN
====================
